ArticleAntimicrobial agents and chemotherapy2020
A Diverse Panel of Clinical Acinetobacter baumannii for Research and Development.
Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 85 citations in OpenAlex.
- Acinetobacter baumannii's lifestyle includes soil-dwelling colonization of decaying plant material and airborne spread.Nature communications · 2026Article
- Preferred evolutionary routes of convergence in Klebsiella pneumoniae favor siderophore acquisition over hypervirulence.Research square · 2026Article
- Article
- Whole-genome sequencing identifies persistent transmission of a high-risk ST2Frontiers in microbiology · 2026Article
- Higher levels of antibiotic resistance are less competitive: the hidden ecological cost of no-metabolic cost resistance.bioRxiv : the preprint server for biology · 2025Article
- PreclinicalAntimicrobial agents and chemotherapy · 2025Article
- Antivirulence drugs against Acinetobacter baumannii: where do they stand?World journal of microbiology & biotechnology · 2025Review
- Article
- Acinetobacter phages use distinct strategies to breach the capsule barrier.PLoS pathogens · 2025Article
- Vancomycin Sensitization inACS infectious diseases · 2025Article
- History shapes regulatory and evolutionary responses to tigecycline in two reference strains ofMicrobiology (Reading, England) · 2025Article
- Phage-encoded enzymes found in Acinetobacter baumannii convert pseudaminic acid to 8-epipseudaminic acid.Communications biology · 2025Article
- Mystique, a broad host range Acinetobacter phage, reveals the impact of culturing conditions on phage isolation and infectivity.PLoS pathogens · 2025Article
- β-Lactamase diversity inAntimicrobial agents and chemotherapy · 2025Article
- Genomic analysis of early ST32 Acinetobacter baumannii strains recovered in US military treatment facilities reveals distinct lineages and links to the origins of the Tn6168 ampC transposon.The Journal of antimicrobial chemotherapy · 2025Article
- Natural peptides and their synthetic congeners acting againstRSC medicinal chemistry · 2025Review
- A phosphorylation signal activates genome-wide transcriptional control by BfmR, the global regulator of Acinetobacter resistance and virulence.Nucleic acids research · 2025Article
- History shapes regulatory and evolutionary responses to tigecycline in strains ofbioRxiv : the preprint server for biology · 2025Article
- Identification of clinically relevant multi-drug resistant ESKAPEE isolates from hospital wastewater surveillance in Thailand.Frontiers in microbiology · 2025Article
- Humoral response induced after intranasal vaccination with heat inactivatedFrontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past two decades,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.